Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

@article{Theodoulou2004CardiacPO,
  title={Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?},
  author={Maria Theodoulou and Clifford A. Hudis},
  journal={Cancer},
  year={2004},
  volume={100 10},
  pages={2052-63}
}
Although conventional doxorubicin is associated with favorable clinical outcomes in patients with a variety of tumor types, it long has been associated with the risk of development of cardiotoxicity. Therefore, researchers have focused their efforts on the development of new formulations to improve efficacy while minimizing associated toxicities. The most successful strategy reported to date has been liposomal encapsulation, which alters the pharmacokinetics of the drug, with the goal of… CONTINUE READING